Inventor · disambiguated record
Marcus Koppitz
Also filed as: KOPPITZ MARCUS · KOPPITZ MARCUS KARL
26 granted patents·28 pending applications·107 citations·filing 1997–2020
94Inventor score
Top patents by PatentIndex Score
54 records- 0196US9549932B22-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2016·Granted Jan 24, 2017·26 cites·30 claims
- 0293US10729680B25-substituted 2-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2017·Granted Aug 4, 2020·10 cites·14 claims
- 0389US9993484B22-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2015·Granted Jun 12, 2018·4 cites·9 claims
- 0485US11529356B22-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2020·Granted Dec 20, 2022·1 cites·20 claims
- 0585US10772893B22-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2018·Granted Sep 15, 2020·2 cites·12 claims
- 0682US9388140B2Substituted benzimidazolesKLAR ULRICH·Filed 2012·Granted Jul 12, 2016·3 cites·18 claims
- 0781US9340528B2Substituted aminoquinoxalines as tyrosine threonine kinase inhibitorsBADER BENJAMIN·Filed 2010·Granted May 17, 2016·12 cites·6 claims
- 0880US7122570B2Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR)ZENTARIS AG·Filed 2002·Granted Oct 17, 2006·21 cites·20 claims
- 0975US9255100B2Substituted imidazopyridazinesKLAR ULRICH·Filed 2011·Granted Feb 9, 2016·3 cites·14 claims
- 1066US9199999B2Substituted imidazopyrazinesKLAR ULRICH·Filed 2011·Granted Dec 1, 2015·1 cites·5 claims
- 1165US9284317B2Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitorsKOPPITZ MARCUS·Filed 2011·Granted Mar 15, 2016·1 cites·10 claims
- 1265US9212184B26-thio-substituted imidazo[1,2-a]pyrazines as Mps-1 inhibitorsKOPPITZ MARCUS·Filed 2011·Granted Dec 15, 2015·1 cites·10 claims
- 1363US8551980B2Substituted triazolopyridinesSCHULZE VOLKER·Filed 2010·Granted Oct 8, 2013·1 cites·13 claims
- 1462US6127335ACyclic adhesion inhibitorsMERCK PATENT GMBH·Filed 1997·Granted Oct 3, 2000·18 cites·5 claims
- 1561US8729082B2Substituted imidazoquinoxalinesKOPPITZ MARCUS·Filed 2010·Granted May 20, 2014·1 cites·13 claims
- 1654US2009082328A1Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activityBAYER HEALTHCARE AG·Filed 2008·Application pending·0 cites
- 1751US9512130B2Substituted imidazopyridazinesBayer Pharma AG·Filed 2014·Granted Dec 6, 2016·0 cites·10 claims
- 1849US2011071125A1Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activityRUDOLPH JOACHIM·Filed 2008·Application pending·0 cites
- 1949US2009075987A1Alkylacetylene substituted acyltryptophanolsWORTMANN LARS·Filed 2008·Application pending·0 cites
- 2048US2009069328A1Alpha-alkyl substituted n-acyltryptophanolsWORTMANN LARS·Filed 2008·Application pending·0 cites
- 2147US2008287493A1Arylmethylen substituted n-acyl-y-aminoalcoholsWORTMANN LARS·Filed 2008·Application pending·0 cites
- 2247US2010029599A1Indolylamides as modulators of the EP2 receptorBAYER SCHERING PHARMA AG·Filed 2009·Application pending·0 cites
- 2346US10730856B2Benzimidazole derivatives as EP4 ligandsBayer Pharma AG·Filed 2014·Granted Aug 4, 2020·0 cites·9 claims
- 2446US2009082372A1Arylmethylene Substituted N-Acyl-Beta-Amino AlcoholsWORTMANN LARS·Filed 2008·Application pending·0 cites
- 2546US2009069321A1Cyanomethyl substituted n-acyl tryptaminesWORTMANN LARS·Filed 2008·Application pending·0 cites
- 2645US2008207728A1Bicyclic acyltryptophanolsWORTMANN LARS·Filed 2007·Application pending·0 cites
- 2744US9512126B2Substituted imidazopyridazinesBAYER IP GMBH·Filed 2013·Granted Dec 6, 2016·0 cites·16 claims
- 2844US2008125435A11-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the EP2 receptorBRAUER NICO·Filed 2007·Application pending·0 cites
- 2944US2017037028A1Glucose transport inhibitorsBayer Pharma AG·Filed 2014·Application pending·0 cites
- 3044US2008221195A11,2-diarylacetylene derivatives of acyltryptophanolsWORTMANN LARS·Filed 2007·Application pending·0 cites
- 3143US2009042913A1Indolylalkylthienopyrimidylamines as modulators of the EP2 receptorBRAEUER NICO·Filed 2008·Application pending·0 cites
- 3243US2009042878A1Thienopyrimidylamines as modulators of the ep2 receptorBRAEUER NICO·Filed 2008·Application pending·0 cites
- 3342US2009023738A1Diaminopyrimidines as modulators of the ep2 receptorBRAEUER NICO·Filed 2008·Application pending·0 cites
- 3442US2020085791A1[(phenylsulfonyl)octahydro-epiminoisoindol-yl](1h-1,2,3-triazol-5-yl)methanonesBayer Pharma AG·Filed 2017·Application pending·0 cites
- 3540US11319324B2Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitorsBAYER AG·Filed 2018·Granted May 3, 2022·0 cites·11 claims
- 3640US10894784B2Heteroarylbenzimidazole compoundsBayer Pharma AG·Filed 2016·Granted Jan 19, 2021·0 cites·15 claims
- 3740US2018148418A1Amido-substituted cyclohexane derivativesBayer Pharma AG·Filed 2016·Application pending·0 cites
- 3840US2008125463A1N-(1-hetarylpiperidin-4-yl)(het)arylamides as EP2 receptor modulatorsBRAEUER NICO·Filed 2007·Application pending·0 cites
- 3939US2013303532A1Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disordersKOPPITZ MARCUS·Filed 2011·Application pending·0 cites
- 4038US10172814B2Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereofBayer Pharma AG·Filed 2015·Granted Jan 8, 2019·0 cites·21 claims
- 4138US2014187548A16 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disordersKOPPITZ MARCUS·Filed 2011·Application pending·0 cites
- 4238US2014255392A1Substituted imidazopyridines and intermediates thereofKOPPITZ MARCUS·Filed 2012·Application pending·0 cites
- 4338US2009023741A1Aryl/hetarylamides as modulators of the ep2 receptorBUCHMANN BERND·Filed 2008·Application pending·0 cites
- 4438US2014135319A16-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disordersKOPPITZ MARCUS·Filed 2011·Application pending·0 cites
- 4538US2009042882A1Substituted acetamides as modulators of the ep2 receptorBUCHMANN BERND·Filed 2008·Application pending·0 cites
- 4637US10167293B2[8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanonesBayer Pharma AG·Filed 2017·Granted Jan 1, 2019·0 cites·18 claims
- 4737US9468642B2ImidazopyrazinesKLAR ULRICH·Filed 2011·Granted Oct 18, 2016·0 cites·16 claims
- 4837US2020123147A1Thiazole compounds useful as prmt5 inhibitorsBAYER AG·Filed 2018·Application pending·0 cites
- 4937US2020079758A1[4-(phenylsulfonyl)piperazin-1-yl](1h-1,2,3-triazol-4-yl)methanonesBayer Pharma AG·Filed 2017·Application pending·0 cites
- 5035US6528619B1Inhibitors for urokinase receptorROCHE DIAGNOSTICS GMBH·Filed 1998·Granted Mar 4, 2003·2 cites·16 claims
Showing the top 50 of 54 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Marcus Koppitz files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →